<div class="headers"><div>Fig. 6 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score: treatment comparisons at 12 weeks for T + O 5/5 µg versus T 5 µg and versus placebo in patients who were treatment naive/not treatment naive at baseline. </div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>35(AI)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Fig. 6 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score: treatment comparisons at 12 weeks for T + O 5/5 µg versus T 5 µg and versus placebo in patients who were treatment naive/not treatment naive at baseline. </p></td>
</tr>
</tbody>
</table>
